Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascletis Pharma Inc.

www.ascletis.com

Latest From Ascletis Pharma Inc.

Coronavirus Notebook: Regeneron, HHS To Develop Antibody

Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.

China Infectious Diseases

Coronavirus Notebook: China Generic Antiviral Filed For Emergency Approval

China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.

China Infectious Diseases

10 For 2020: Regulatory Trends To Watch In China

2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.

China Regulation

Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a  new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.

Appointments Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Ascletis Pharma Inc.
  • Senior Management
  • Jinzi J Wu, PhD, Pres. & CEO
    Yuemei Yan, VP, Sales
    Zhengqing Li, PhD, CMO
    Handan He, PhD, CSO
  • Contact Info
  • Ascletis Pharma Inc.
    Phone: 571- 8538-9729
    1785 Jianghai Rd., Bldg. 4, Ste. 1801
    Hangzhou, NC
    China
UsernamePublicRestriction

Register